Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab biosimilar CMAB302 + vinorelbine
- Development stage
- Unknown
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Combination therapy of the trastuzumab biosimilar **CMAB302** (Cipterbin)—a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2)—with **vinorelbine**, a small-molecule anti-mitotic chemotherapy agent belonging to the vinca alkaloid class. CMAB302 binds HER2 to inhibit cell proliferation in HER2-positive tumors via antibody-dependent cellular cytotoxicity and inhibition of downstream signaling. Vinorelbine disrupts microtubule assembly, preventing mitotic spindle formation and cell division. This combination is under investigation for HER2-positive metastatic breast cancer and is primarily developed for cost-effective oncological care, especially in China[1].
- Brand names
- Cipterbin
- Other names
- trastuzumab biosimilar CMAB302vinorelbineNavelbine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)MicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on trastuzumab biosimilar CMAB302 + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab biosimilar CMAB302 + vinorelbine.